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Serotype-cross-reactive dengue virus-specific cytotoxic T lymphocytes (CTL) induced during a primary
dengue virus infection are thought to play a role in the immunopathogenesis of dengue hemorrhagic fever
(DHF) during a secondary dengue virus infection. Although there is no animal model of DHF, we previously
reported that murine dengue virus-specific CTL responses are qualitatively similar to human dengue virus-
specific CTL responses. We used BALB/c mice to study the specificity of the CTL response to an immuno-
dominant epitope on the dengue virus NS3 protein. We mapped the minimal H-2Kd-restricted CTL epitope to
residues 298 to 306 of the dengue type 2 virus NS3 protein. In short-term T-cell lines and clones, the
predominant CD81 CTL to this epitope in mice immunized with dengue type 2 virus or vaccinia virus
expressing the dengue type 4 virus NS3 protein were cross-reactive with dengue type 2 or type 4 virus, while
broadly serotype-cross-reactive CTL were a minority population. In dengue type 3 virus-immunized mice, the
predominant CTL response to this epitope was broadly serotype cross-reactive. All of the dengue virus-specific
CTL clones studied also recognized the homologous NS3 sequences of one or more closely related flaviviruses,
such as Kunjin virus. The critical contact residues for the CTL clones with different specificities were mapped
with peptides having single amino acid substitutions. These data demonstrate that primary dengue virus
infection induces a complex population of flavivirus-cross-reactive NS3-specific CTL clones in mice and
suggest that CTL responses are influenced by the viral serotype. These findings suggest an additional mech-
anism by which the order of sequential flavivirus infections may influence disease manifestations.
The family Flaviviridae consists of over 65 arthropod-trans-
mitted viruses that are known to infect humans. The dengue
viruses, of which there are four serotypes, are the flaviviruses
of greatest global health importance, causing an estimated 100
million infections each year (10, 28). Dengue hemorrhagic
fever (DHF), the severe clinical form of dengue virus infection,
has been shown to occur more frequently in individuals who
have experienced a previous infection with a different dengue
virus serotype (1, 37, 40), suggesting an immunopathologic
basis for severe dengue illness.
Members of our laboratory have been studying memory den-
gue virus-specific cytotoxic T-lymphocyte (CTL) responses in
order to understand the potential protective and immuno-
pathologic effects of these CTLs during secondary dengue virus
infections. CD41 and CD81 CTL responses induced by pri-
mary dengue virus infection have been characterized with bulk
cultures and at the clonal level in a small number of adult
human volunteers who were infected under experimental con-
ditions with live tissue culture-passaged dengue viruses (8, 17,
18, 23, 27). Both serotype-specific and serotype-cross-reactive
CTLs have been isolated from most subjects. Most serotype-
cross-reactive CTLs have been directed at epitopes on non-
structural proteins, particularly the NS1-NS2A and NS3 pro-
teins. Several different patterns of cross-reactivity have been
observed; some CTL clones have recognized several but not all
dengue virus serotypes, other clones have recognized all four
dengue virus serotypes, and other clones have also recognized
closely related flaviviruses, such as West Nile virus (WNV)
(14). The frequencies of different CTL specificities have varied
among the subjects studied; however, it has not been possible
to relate these differences to host factors, such as HLA type, or
differences in the viruses causing primary infections.
We previously reported that T-lymphocyte responses to pri-
mary dengue virus infection in mice are qualitatively similar to
human T-lymphocyte responses to dengue virus in bulk cul-
tures and at the clonal level (34–36). Both serotype-specific
and serotype-cross-reactive dengue virus-specific CTL clones
were isolated from BALB/c mice, and the serotype-cross-reac-
tive clones recognized epitopes on the NS1-NS2A and NS3
proteins. One CD81 CTL epitope, recognized in the context of
H-2Kd, was mapped to amino acids 296 to 310 of the dengue
type 2 virus NS3 protein (34). This epitope is completely con-
served in dengue type 4 virus.
To define further the potential importance of these memory
dengue virus-specific CD81 CTLs in secondary dengue virus
infection, we analyzed in more detail the specificity of the
NS3-specific CTL clones. As reported here, we noted that all
four serotypes of dengue viruses as well as closely related
flaviviruses showed a high degree of amino acid homology at
the epitope mentioned above. Specific single amino acid dif-
ferences in this epitope had different effects on recognition by
different CTL clones, accounting for both dengue virus sub-
complex-specific and dengue virus complex-cross-reactive pat-
terns of responses. We also explored the effects of the infecting
virus on the patterns of CTL responses generated.
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MATERIALS AND METHODS
Cells. Target cell lines were the P815 murine mastocytoma line (H-2d), L929
(H-2k) cell lines transfected with Ld (T1.1.1) or Dd (T4.8.3) and provided by
Carol Reiss of New York University (26), and an L929 cell line transfected with
Kd(L-Kd-172) and obtained from Jack Bennick of the National Institutes of
Health (5). The control L929 cell line (DAP) was a gift from Carol Reiss.
Viruses. Mouse-adapted dengue type 2 virus (strain New Guinea C), type 3
virus (strain PR6), and type 4 virus (strain 814669) were kindly provided by Jack
McCown of the Walter Reed Army Institute of Research. Tissue culture-adapted
dengue type 2 virus (strain New Guinea C) was graciously donated by Walter
Brandt, also of the Walter Reed Army Institute of Research, and was propagated
in C6/36 cells. Recombinant vaccinia viruses expressing the dengue type 2 or type
3 virus NS3 protein were provided by Margo Brinton of Georgia State University
(41), and a recombinant vaccinia virus expressing the dengue type 4 virus NS3
protein was provided by Ching-Juh Lai of the National Institutes of Health (6,
35).
Peptides. Synthetic peptides were prepared by 9-fluorenylmethoxycarbonyl
chemistry with a Symphony automated peptide synthesizer (Rainin Instruments,
Woburn, Mass.) at the Peptide Core Facility at the University of Massachusetts
Medical Center.
Mouse immunization and preparation of spleen cells. Immunization of mice
and preparation of clones from spleen cells were performed as previously de-
scribed (34–36). Briefly, male BALB/c (H-2d) mice (Charles River Breeding
Laboratories, Wilmington, Mass.) were immunized at 4 to 8 weeks of age with
dengue virus (0.2 to 0.3 ml containing approximately 1 3 106 PFU) or with one
to three doses of recombinant vaccinia virus expressing the dengue virus NS3
protein (0.1 ml containing approximately 2 3 107 PFU). Splenocytes were col-
lected 4 to 8 weeks after immunization and incubated in RPMI 1640 medium
with 5 3 105 M 2-mercaptoethanol, 10% fetal calf serum (Hyclone Laboratories,
Logan, Utah), and 0.5 ml of dengue virus or 1 mM peptide. Approximately every
2 weeks, the cells were stimulated with either 2 3 106 gamma-irradiated dengue
type 2 virus-infected P815 cells or 3 3 107 gamma-irradiated syngeneic nonim-
mune spleen cells plus 1 mM dengue virus NS3 peptide. Cells were fed twice
weekly with medium containing 10% rat lectin-free T-cell growth factor as a
source of interleukin 2.
Cytotoxicity assays. Cytotoxicity assays were performed as previously de-
scribed (34, 35). Briefly, P815 cells were radioactively labeled by incubation with
Na251CrO4 for 1 h, washed extensively, and seeded at 0.5 3 104 cells per well in
96-well U-bottom plates. Serial dilutions of peptides were added directly to the
target cells in the wells. The clones were then added at various effector/target cell
ratios. The plates were incubated at 37°C for 4 h. The supernatant fluid was
collected with a Supernatant Collecting System (Skatron, Inc., Sterling, Va.). A
gamma counter detected the release of 51Cr. Minimum 51Cr release was mea-
sured by sampling supernatant fluid from labeled target cells incubated in me-
dium alone. Maximum 51Cr release was determined from wells in which labeled
target cells were incubated with Renex. Assays were performed in triplicate, and
the mean of the samples was used to calculate percent specific lysis with the
following formula: percent specific lysis 5 100 3 [(experimental 51Cr release 2
minimum 51Cr release)/(maximum 51Cr release 2 minimum 51Cr release)]. Min-
imum 51Cr release did not exceed 30% of maximum 51Cr release. Lysis of
peptide-coated target cells was considered significant when it was $8% more
than lysis of target cells in the absence of peptides and values were found
significantly different by the Student t test.
RESULTS
Identification of the minimal epitope recognized by NS3-
specific CTL clones. We previously mapped a dominant
epitope on the dengue type 4 virus NS3 protein recognized by
H-2Kd-restricted CD81 CTL clones derived from dengue type
2 virus-immunized BALB/c mice to a 15-amino-acid region
between residues 296 and 310, ARGYISTRVEMGEAA (34).
To define further the specific epitope recognized by these CTL
clones, we tested for the recognition of target cells incubated
with truncations of this 15-mer. Data obtained with clone 2D65
are shown in Table 1; similar data were obtained with clone
2D42 (data not shown). Initial data suggested that the minimal
sequence was the 9-mer representing residues 298 (G) to 306
(M). Analysis of recognition of this 9-mer peptide and trunca-
tions thereof showed that the C-terminal methionine was re-
quired for recognition by these CTL clones. The 8-mer peptide
representing residues 299 to 306 could be recognized by these
clones, but recognition of this peptide was reproducibly less
efficient than recognition of the 9-mer peptide representing
residues 298 to 306.
CTL clones derived from dengue type 2 virus-immunized
mice recognize the corresponding sequence of dengue type 4
but not dengue type 1 or dengue type 3 virus. We previously
reported that the sequence of the 15-mer recognized by the
CTL clones was completely conserved between dengue type 2
and dengue type 4 viruses (34). We next examined the pub-
lished sequences to determine the corresponding sequences of
other dengue virus serotypes and related flaviviruses (Table 2)
(2, 3, 7, 13, 22, 25, 30, 33, 39). This analysis showed that this
region of the NS3 protein is highly conserved among flavivi-
ruses. Compared to the dengue type 2 or type 4 virus sequence,
there was only a single amino acid difference at peptide posi-
tion 8 in dengue type 1 and dengue type 3 viruses, a single
amino acid difference at position 9 in Kunjin virus, and two
amino acid differences in Murray Valley encephalitis virus.
WNV and Japanese encephalitis virus had three amino acid
differences, and the less closely related yellow fever virus had
seven amino acid differences.
Since serotype cross-reactivity is most clinically relevant
among the dengue viruses, we first tested for recognition of the
dengue type 1 or type 3 virus sequence by the CTL clones (Fig.
1). Identical results were obtained with recombinant vaccinia
viruses expressing the full-length NS3 proteins of dengue type
2, dengue type 3, and dengue type 4 viruses or synthetic pep-
tides representing the dengue type 2 or type 4 virus or the
dengue type 1 or type 3 virus sequences; none of six clones
isolated from dengue type 2 virus-immunized mice recognized
the dengue type 3 virus NS3 sequence.
Dengue type 4 virus NS3-immunized mice do have serotype-
cross-reactive CTL responses. We next tested whether the
dengue type 1 or type 3 virus NS3 sequences could be recog-
nized by H-2Kd-restricted CTLs. Splenocytes from mice immu-
nized with a recombinant vaccinia virus expressing the dengue
type 4 virus NS3 protein were stimulated in bulk cultures with
the dengue type 4 virus NS3 peptide (296 to 310) and tested for
recognition of the dengue type 2 or type 4 virus and dengue
type 1 or type 3 virus NS3 peptides (Table 3). At day 40 of
culturing, the predominant response was specific for the den-
gue type 4 virus NS3 sequence, but there was significant, if less
efficient, recognition of the dengue type 3 virus NS3 peptide.
This result suggested that serotype-cross-reactive CTLs were
present but at a lower level than CTLs specific for the dengue
type 2 or type 4 virus peptide. The bulk cultures were then split
TABLE 1. Recognition of truncations of the dengue type 4 virus
NS3 peptide (residues 296 to 310) by CD81 CTL clone 2D65a
Expt Peptideresidues Sequence
% Specific lysis
at peptide concn of:
5 mM 500 nM 50 nM 5 nM
1 296–310 ARGYISTRVEMGEAA 56 23 3 2
298–310 GYISTRVEMGEAA 58 55 36 10
300–310 ISTRVEMGEAA 1 2 2 2
296–308 ARGYISTRVEMGE 58 34 6 5
296–306 ARGYISTRVEM 59 32 5 3
2 298–306 GYISTRVEM 25 27 27 18
298–305 GYISTRVE 6 3 11 5
299–306 YISTRVEM 21 19 18 9
300–306 ISTRVEM 9 2 4 9
a Recognition of synthetic peptide-pulsed target cells was tested at effector/
target cell ratios of 4:1 in experiment 1 and 2:1 in experiment 2. Percentages of
lysis of target cells in the absence of peptide were 2% in experiment 1 and 9%
in experiment 2. Boldface values represent percent specific lysis significantly
greater than that of the negative control.
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and restimulated with either the dengue type 4 or the dengue
type 3 virus NS3 peptide. The CTL lines were then tested for
recognition of both peptides. The CTL line restimulated with
the dengue type 4 virus NS3 peptide maintained recognition of
the dengue type 4 virus NS3 peptide but showed little if any
recognition of the dengue type 3 virus NS3 peptide at day 54 of
culturing. In contrast, the CTL line restimulated with the den-
gue type 3 virus NS3 peptide showed a high level of cross-
reactivity for both peptides. Both CTL lines recognized the
target epitope in an H-2Kd-restricted manner (data not
shown). These results suggest that serotype-cross-reactive
CTLs were initially present at a low level but that they could be
selectively expanded by stimulation with the dengue type 3
virus NS3 peptide.
We then used this stimulation protocol to isolate dengue
virus serotype-cross-reactive CD81 CTL clones. Splenocytes
from mice immunized with dengue type 4 virus were stimulated
with the dengue type 3 virus NS3 peptide and cloned by lim-
iting dilution. Five CTL clones were isolated; all recognized
both the dengue type 4 and the dengue type 3 virus NS3
peptides in the context of H-2Kd (data not shown).
Dengue virus NS3-specific CTL from dengue type 3 virus-
immunized mice are serotype cross-reactive. We wanted to
characterize further the serotype cross-reactivity of dengue
virus NS3-specific CTL lines. We immunized mice with dengue
type 3 virus to determine the pattern of CTL serotype cross-
reactivity induced by the dengue type 3 virus NS3 epitope.
Splenocytes from dengue type 3 virus-immunized mice were
stimulated in vitro with the dengue type 3 virus NS3 peptide
and tested for the recognition of the dengue type 1 or type 3
virus and dengue type 2 or type 4 virus NS3 peptides (Table 4).
These CTLs lysed target cells pulsed with either peptide, indi-
cating that the predominant CTL response in dengue type 3
virus-immunized mice is broadly dengue virus serotype cross-
reactive. These CTLs also lysed target cells infected with re-
combinant vaccinia viruses expressing either the dengue type 2,
dengue type 3, or dengue type 4 virus NS3 protein or target
cells infected with dengue type 2 virus, indicating that these
CTLs recognize the naturally processed epitope (Table 4). We
isolated 14 CTL clones from this CTL line by limiting dilution;
all the clones isolated recognized both the dengue type 3 and
the dengue type 4 virus NS3 peptides in the context of H-2Kd
(data not shown).
Flavivirus specificity of dengue virus NS3-specific CTL
clones. We next studied the specificity of the CTL clones for
other closely related flaviviruses. Representative data obtained
with CTL clones each corresponding to the different specific-
ities are shown in Fig. 2. Clone 2D42, which was generated
from dengue type 2 virus-immunized mice after stimulation
with dengue type 2 virus-infected P815 cells, did not recognize
the dengue type 1 or type 3 virus peptide but did recognize the
homologous peptides of Kunjin virus and Murray Valley en-
cephalitis virus. Clone E10.6, which was generated from a
dengue type 4 virus-immunized mouse after stimulation with
the dengue type 3 virus NS3 peptide, recognized the NS3
peptides from all dengue virus serotypes and Kunjin virus. This
clone could recognize the Murray Valley encephalitis virus
sequence but less efficiently than clone 2D42. Clone 0.5-1,
which was generated from dengue type 3 virus-immunized
mice after stimulation with the dengue type 3 virus NS3 pep-
tide, was similarly dengue virus serotype cross-reactive and
able to recognize the Kunjin virus peptide but did not show any
recognition of the Murray Valley encephalitis virus peptide.
None of the three clones recognized the homologous peptides
of Japanese encephalitis virus, WNV, or yellow fever virus.
FIG. 1. Dengue virus serotype specificity of CD81 CTL clones isolated from
dengue type 2 virus-immunized mice. Clones 2D42 (hatched bars) and 2D65
(open bars) were isolated from dengue type 2 virus-immunized BALB/c mice and
tested at an effector/target cell ratio of 4:1. P815 target cells were uninfected (2);
infected with dengue type 2 virus (D2V), wild-type vaccinia virus (vvCont), or
recombinant vaccinia viruses (vv) expressing the full-length dengue type 2, den-
gue type 3, or dengue type 4 virus NS3 proteins (vvD2NS3, vvD3NS3, and
vvD4NS3, respectively); or pulsed with the dengue type 4 virus (residues 296 to
310) or dengue type 3 virus (residues 297 to 311) peptides (D4-NS3 peptide and
D3-NS3 peptide, respectively) at 10 mM.
TABLE 2. Sequences of dengue virus and related flaviviruses at the
CD81 CTL epitope
Virus Sequence Reference
Dengue type 4 298GYISTRVEM306 25
Dengue type 1 299-------G-307 7
Dengue type 2 298---------306 13
Dengue type 3 299-------G-307 30
Kunjin 299--------L307 3
Murray Valley encephalitis 299---A----A307 22
WNV 299---A-K--L307 2
Japanese encephalitis 299---A-K--L307 39
Yellow fever 303-WAAH-ARA311 33
TABLE 3. Recognition of dengue virus NS3 peptides by short-term
CTL lines from dengue type 4 virus NS3-immunized micea
Day Dengue virus type usedto stimulate cell lines
Target
cellsb
% Specific lysis
at peptide concn of:
1 mM 100 nM 10 nM —
40 4c D4-NS3 79 75 69 1
D3-NS3 40 22 13
54 4c D4-NS3 46 48 42 7
D3-NS3 10 5 2
433d D4-NS3 47 50 46 2
D3-NS3 41 36 25
a BALB/c mice were immunized with a recombinant vaccinia virus expressing
the dengue type 4 virus NS3 protein. Boldface values represent percent specific
lysis significantly greater than that of the negative control (no peptide [—]).
b P815 target cells were incubated with the corresponding peptides of dengue
type 4 virus (D4-NS3) or dengue type 3 virus (D3-NS3).
c Spleen cells from immunized mice were stimulated in vitro with the D4-NS3
peptide.
d Spleen cells from immunized mice were initially stimulated in vitro with the
D4-NS3 peptide for 40 days and then stimulated with the corresponding D3-NS3
peptide.
400 SPAULDING ET AL. J. VIROL.
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
Identification of the critical contact residues for dengue
virus-specific CTL clones. The different patterns of recogni-
tion of related flaviviruses suggested that the clones differed in
the critical contact residues of the NS3 peptide. To character-
ize this idea further, we tested the three above-mentioned
clones for the recognition of peptides with individual substitu-
tions at each of the nine residues of the dengue type 4 virus
NS3 sequence. To facilitate the comparison of the recognition
of these peptides and the peptides of the related flaviviruses,
we based the substitutions on the corresponding amino acids of
other flaviviruses, except for position 1, where we substituted
alanine for the conserved glycine. Recognition of these pep-
tides by clones 2D42, E10.6, and 0.5-1 is shown in Fig. 3.
The second and ninth residues are most important for bind-
ing to H-2Kd (32). Substitution of tryptophan for tyrosine at
the second residue, as in yellow fever virus, abolished recog-
nition by clones E10.6 and 0.5-1 and drastically inhibited rec-
ognition by clone 2D42. Substitution of leucine for methionine
at the ninth position, as in Kunjin virus, did not impair recog-
nition by any of the clones, in keeping with the known suit-
ability of leucine at this position for binding to Kd (32). Sub-
stitution of histidine for threonine at the fifth residue, as in
yellow fever virus, impaired recognition by all clones. Peptide
recognition by clone 2D42 was also inhibited by substitutions at
positions 6, 7, and 8, which included the single substitution in
the dengue type 1 or type 3 virus peptide. In comparison,
peptide recognition by clones E10.6 and 0.5-1 was inhibited
most by substitutions at positions 3 and 4.
DISCUSSION
This study expands on our previous work showing that
H-2Kd-restricted CD81 CTL clones isolated from dengue type
2 virus-immunized BALB/c mice recognize a dengue type 2
and type 4 virus-cross-reactive epitope between amino acids
296 and 310 of the NS3 protein (34). We defined the minimal
epitope as amino acids 298 to 306 of the dengue type 2 virus
NS3 protein. We also generated additional CD81 CTL clones
that recognized the same epitope from mice immunized with
dengue type 3 or dengue type 4 virus. We found that these CTL
clones were either dengue virus subcomplex (dengue type 2 or
type 4 virus) specific or broadly serotype cross-reactive. In
addition, all of these CTL clones recognized the corresponding
sequences of one or more other flaviviruses.
The NS3 protein appears to be a dominant target for dengue
virus-specific CD41 and CD81 T cells, and most dengue virus
NS3-specific T cells are serotype cross-reactive (14, 27, 35).
Multiple human CD41 T-cell epitopes on the NS3 protein
have been identified (15, 19, 21, 29, 41). Although few human
CD81 T-cell epitopes have been mapped on the NS3 protein,
bulk-culture CD81 CTL recognition of the NS3 protein was
detected in six of eight dengue virus-immunized subjects in one
study (27). CTLs from several mouse strains have been found
to recognize the NS3 protein of dengue virus as well as other
flaviviruses, including WNV, Murray Valley encephalitis virus,
and Kunjin virus (11, 24, 31, 35). The abundance of T-cell
epitopes on the flavivirus NS3 protein is not well explained.
The relative conservation of the NS3 protein among flavivi-
ruses suggests that the requirements for the enzymatic func-
tions of this protein may restrict the ability of flaviviruses to
survive mutations. The minimal peptide recognized by the
H-2Kd-restricted CTLs that we studied, GYISTRVEM, con-
FIG. 2. Flavivirus specificity of CD81 CTL clones. Clones 2D42, E10.6, and
0.5-1 were tested in separate experiments. Virus sequences are designated as
follows: D4, dengue type 4 (identical to dengue type 2); D3, dengue type 3
(identical to dengue type 1); KUN, Kunjin; MVE, Murray Valley encephalitis;
JEV, Japanese encephalitis (identical to WNV); and YFV, yellow fever. Data are
expressed as a percentage of the D4 response, calculated as 100 3 [(percent
specific lysis of target cells incubated with indicated peptide)/(percent specific
lysis of target cells incubated with the dengue type 4 virus peptide)]. For clone
2D42, the effector/target cell ratio was 1:1, and percentages of specific lysis were
as follows: no peptide, 3%; 5,000 nM, 36%; 500 nM, 35%; 50 nM, 36%; and 5
nM, 30%. For clone E10.6, the effector/target cell ratio was 2:1, and percentages
of specific lysis were as follows: no peptide, 5%; 5,000 nM, 58%; 500 nM, 59%;
50 nM, 65%; and 5 nM, 55%. For clone 0.5-1, the effector/target cell ratio was
2:1, and percentages of specific lysis were as follows: no peptide, 23%; 5,000 nM,
29%; 500 nM, 30%; 50 nM, 28%; and 5 nM, 27%.
TABLE 4. Serotype cross-reactivity of NS3-specific CTLs in dengue
type 3 virus-immunized micea
Day of culturing Target cellsb % Specific lysis
27 D4-NS3 (298–306) 25
D3-NS3 (299–307) 27
WNV NS3 (299–307) 4
40 D2V 57
Uninfected 22
vvD2:NS3 31
vvD3:NS3 43
vvD4:NS3 25
vvControl 1
a Spleen cells from mice immunized with dengue type 3 virus were stimulated
in vitro with the dengue type 3 virus NS3 (D3-NS3) peptide (residues 299 to 307)
and tested for recognition of the indicated target cells. Boldface values represent
percent specific lysis significantly greater than that of the negative control.
b P815 target cells were incubated with the corresponding peptides of dengue
type 4 virus, dengue type 3 virus, or WNV (day-27 effectors) or were infected
with dengue type 2 virus (D2V), wild-type vaccinia virus (vvControl), or recom-
binant vaccinia viruses (vv) expressing the dengue type 2, dengue type 3, or
dengue type 4 virus NS3 proteins (day-40 effectors) (e.g., vvD2:NS3 represents
dengue type 2 virus NS3 protein expressed by a recombinant vaccinia virus).
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tains the typical Kd binding motif, with tyrosine at position 2
and a hydrophobic amino acid at position 9 (32). This Kd
binding motif is conserved in Kunjin virus, Murray Valley
encephalitis virus, WNV, and Japanese encephalitis virus, sug-
gesting that this epitope may be recognized by CTLs induced in
mice by infection with these flaviviruses.
Memory dengue virus serotype cross-reactive CTLs may
play a protective role in limiting viral replication, but they have
also been proposed to contribute to the increased risk for DHF
during secondary dengue virus infections (20). Levels of solu-
ble CD8 in serum were found to be elevated in children with
DHF compared to those with dengue fever, supporting an
immunopathologic role for CD81 CTLs (7a, 16). The NS3-
specific CTL clones that we studied recognized one or more
heterologous dengue virus serotypes and theoretically could be
activated during a secondary dengue virus infection.
These results also demonstrate CTL cross-reactivity with
other flaviviruses, specifically Kunjin and Murray Valley en-
cephalitis viruses, which have the most homology with dengue
viruses at the epitope in question. Similarly, Kurane et al.
reported that some human dengue virus-specific CD41 CTL
clones could recognize WNV or yellow fever virus (14). Inter-
estingly, not all flavivirus-cross-reactive CTL clones isolated
from dengue virus-immunized humans and mice were able to
recognize all four dengue virus serotypes (41). We used pep-
tides incorporating single substitutions into the background of
the dengue type 2 or type 4 virus NS3 peptide sequence to
explain this unexpected pattern of specificity. Peptide recogni-
tion by clone 2D42, which recognized the dengue type 2 or type
4, Kunjin, and Murray Valley encephalitis virus sequences, was
sensitive to the substitution at position 8 in the dengue type 1
or type 3 virus sequence, whereas substitutions at positions 4
and 9, as in Murray Valley encephalitis virus, had little effect.
In contrast, clone 0.5-1, which was broadly dengue virus sero-
type cross-reactive but unable to recognize the Murray Valley
encephalitis virus sequence, was unaffected by the substitution
at position 8 but was unable to recognize the peptide incorpo-
rating the position 4 substitution.
CTL cross-reactivity with other flaviviruses suggests that
protective and immunopathologic effects might occur during
sequential infections with flaviviruses other than dengue virus.
In a large field study of a Japanese encephalitis virus vaccine,
Hoke et al. observed that the incidence of DHF was somewhat
lower in immunized children than in control subjects over a
2-year period, although the difference was not statistically sig-
nificant (12). Several studies have also found that the antibody
response to candidate live dengue virus vaccines was enhanced
in subjects previously immunized with a yellow fever virus
vaccine (4, 38). Epidemiologic studies have not fully addressed
this possibility, in part because the geographic distribution of
dengue virus has historically overlapped that of only Japanese
encephalitis virus. More recently, however, dengue virus infec-
tions have become more frequent in areas of the Western
Hemisphere where yellow fever is endemic and in Australia
where Kunjin and Murray Valley encephalitis viruses circulate
(9). These epidemiologic changes increase the opportunities
for sequential flavivirus infections.
We found that the patterns of dengue virus serotype cross-
reactivity in short-term T-cell lines and clones differed in mice
immunized with different dengue virus serotypes. In BALB/c
mice immunized with dengue type 2 virus or a recombinant
vaccinia virus expressing the dengue type 4 virus NS3 protein,
the predominant CTL responses were dengue type 2 or type 4
virus cross-reactive, with a low level of CTL recognition of the
dengue type 1 or type 3 virus sequence. In mice immunized
with dengue type 3 virus, the CTL responses to this epitope
were broadly serotype cross-reactive. Substantial variability in
the levels of serotype-cross-reactive T-cell responses have been
noted in studies of dengue virus-immunized humans, but an
effect of the viral serotype on these responses has not been
apparent. In studies of murine CTL responses to WNV and
Kunjin virus, Hill et al. also noted nonreciprocal CTL flavivirus
cross-reactivity (11). Although a detailed analysis of the levels
of CTLs with different specificities, such as by use of intracel-
lular gamma interferon staining in response to peptide stimu-
lation, would be necessary to provide a definitive demonstra-
tion of this effect, our data suggest that there is nonreciprocal
CTL cross-reactivity among the dengue virus serotypes as well.
Epidemiologic studies have suggested that the order of ac-
quisition of dengue virus infections is important; specifically,
having a sequence of infections in which dengue type 2 virus is
the agent of secondary dengue virus infection increases the
odds of DHF or dengue shock syndrome (37, 40). Differences
in virulence between the different dengue virus serotypes have
been proposed to explain this finding. Our results raise another
possible explanation, that CTLs induced by other serotypes
may recognize dengue type 2 virus to a greater extent than the
reverse.
The full story on the importance of T-cell immunity in DHF
pathogenesis is not yet known, but clarifying the specificity and
cross-reactivity of T-cell clones could give insights into how
cell-mediated immunity might work in nature. Although den-
FIG. 3. Effects of single amino acid substitutions on recognition by dengue
virus-specific CTL clones. Clones 2D42, E10.6, and 0.5-1 were tested in separate
experiments. Data are expressed as a percentage of the response to dengue type
4 virus, calculated as described in the legend to Fig. 2. The peptide designation
specifies the amino acid and position number in the dengue type 4 virus NS3
sequence followed by the substituted amino acid. Peptides E305G and M306L
are the dengue type 3 virus and Kunjin virus peptides, respectively.
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gue virus-infected mice do not manifest DHF, our results sug-
gest that the immune response to sequential dengue virus
infection in mice may provide information useful for directing
further human studies.
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